Roche Experimenting With New Pricing Models In Oncology

Cancer drug prices are unsustainable and creative approaches are needed, Roche’s O’Day says. The firm’s moves into emerging markets are a lab for new methods, he said, though the real test will come as the more expensive drugs are used in combination.